1. Home
  2. SA vs ELVN Comparison

SA vs ELVN Comparison

Compare SA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seabridge Gold Inc. (Canada)

SA

Seabridge Gold Inc. (Canada)

SELL

Current Price

$25.11

Market Cap

2.8B

ML Signal

SELL

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

SELL

Current Price

$47.40

Market Cap

4.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SA
ELVN
Founded
1979
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
4.2B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
SA
ELVN
Price
$25.11
$47.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
14
Target Price
$59.06
★ $74.33
AVG Volume (30 Days)
519.5K
★ 1.4M
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.17
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.26
$14.79
52 Week High
$40.06
$62.32

Technical Indicators

Market Signals
Indicator
SA
ELVN
Relative Strength Index (RSI) 45.15 53.29
Support Level $24.01 $44.18
Resistance Level $28.01 $47.88
Average True Range (ATR) 1.29 2.27
MACD 0.10 0.54
Stochastic Oscillator 35.71 48.14

Price Performance

Historical Comparison
SA
ELVN

About SA Seabridge Gold Inc. (Canada)

Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Share on Social Networks: